source
- STAT+: Johnson & Johnson advances IBD therapy, despite trial missA closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.STAT · 2mo ago↗ source
- STAT+: French regulator fines Novo and Lilly over weight loss ad campaignsFrance's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.STAT · 2mo ago↗ source
- Opinion: Mifepristone court ruling makes drug development riskier for everyoneThe 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.STAT · 2mo ago↗ source